2019
Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium
Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, Szender JB, Odunsi K, Almohanna H, Mayor P, Starbuck K, Zsiros E, Bandera EV, Cramer DW, Doherty JA, DeFazio A, Edwards R, Goode E, Goodman M, Høgdall E, Matsuo K, Mizuno M, Nagle C, Ness R, Paddock L, Pearce C, Risch H, Rossing M, Terry K, Wu A, Modugno F, Webb P, Moysich K. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes & Control 2019, 30: 537-547. PMID: 30905014, PMCID: PMC6614876, DOI: 10.1007/s10552-019-01157-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalOvarian cancer patientsOverweight/obesityBody mass indexPhysical inactivityCurrent smokingCancer patientsJoint exposureExcessive weightHazard ratioOverall survivalLifestyle factorsCox proportional hazards regression modelNormal body mass indexProportional hazards regression modelsInvasive epithelial ovarian carcinomaPurposePrevious epidemiologic studiesUnfavorable lifestyle factorsRisk of deathEpithelial ovarian carcinomaOvarian cancer survivalHazards regression modelsRisk of mortalityConfidence intervalsOvarian Cancer Association Consortium
2017
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium
Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Ness R, Edwards R, Jensen A, Kjær S, Høgdall E, Berchuck A, Cramer D, Terry K, Poole E, Bandera E, Paddock L, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Pearce C, Wu A, Pike M, Webb P. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal Of Cancer 2017, 116: 1223-1228. PMID: 28350790, PMCID: PMC5418444, DOI: 10.1038/bjc.2017.68.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsDisease-specific survivalOvarian cancer survivalAnalgesic useCancer survivalOvarian cancerInvasive epithelial ovarian cancerCommon analgesic medicationsPost-diagnosis usePre-diagnosis useRegular analgesic useEpithelial ovarian cancerOvarian Cancer Association ConsortiumAnti-inflammatory drugsAnalgesic medicationOverall survivalImproved survivalPooled analysisCommon analgesicsSurvival advantageConsortium studyClear associationCancerSurvivalFurther investigationCigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies
Præstegaard C, Jensen A, Jensen SM, Nielsen TS, Webb PM, Nagle CM, DeFazio A, Group O, Høgdall E, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Moysich K, Ness R, Edwards R, Matsuo K, Hosono S, Goode E, Winham S, Fridley B, Cramer D, Terry K, Schildkraut J, Berchuck A, Bandera E, Paddock L, Massuger L, Wentzensen N, Pharoah P, Song H, Whittemore A, McGuire V, Sieh W, Rothstein J, Anton‐Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry‐Maharaj A, Wu A, Pearce C, Pike M, Lee A, Sutphen R, Chang‐Claude J, Risch H, Kjaer S, Consortium O. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal Of Cancer 2017, 140: 2422-2435. PMID: 28063166, PMCID: PMC5489656, DOI: 10.1002/ijc.30600.Peer-Reviewed Original ResearchConceptsPooled hazard ratioCigarette smokingOvarian Cancer Association ConsortiumOvarian cancerHazard ratioPooled analysisStudy-specific hazard ratiosLarge pooled analysisMucinous ovarian tumorsOvarian cancer stageEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsOvarian cancer prognosisCase-control studyRandom-effects modelPotential clinical importanceMedian followAdverse survivalCurrent smokingDisseminated diseaseFormer smokersWorse survivalModifiable factorsOvarian tumors
2016
Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium
Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB, on behalf of The Australian Ovarian Cancer Study Group. Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal Of Cancer 2016, 115: 95-101. PMID: 27299959, PMCID: PMC4931371, DOI: 10.1038/bjc.2016.153.Peer-Reviewed Original ResearchConceptsRecreational physical activityOvarian Cancer Association ConsortiumInvasive EOCHazard ratioPhysical inactivityPooled analysisPhysical activityEpithelial ovarian cancer survivalWeekly recreational physical activityInvasive epithelial ovarian cancerCox proportional hazards modelLarge pooled analysisRecreational physical inactivityPhysical activity guidelinesEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsHigher mortality riskProportional hazards modelActivity guidelinesResidual diseaseCancer survivalPrimary diagnosisOvarian cancerInactive women
2015
Ovarian cancer survival by tumor dominance, a surrogate for site of origin
Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J. Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes & Control 2015, 26: 601-608. PMID: 25771796, PMCID: PMC4561551, DOI: 10.1007/s10552-015-0547-y.Peer-Reviewed Original ResearchConceptsDominant tumorHazard ratioFallopian tubeEstrogen hormone replacement therapyConclusionThese preliminary findingsHormone replacement therapyDistal fallopian tubeRisk of deathEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsProportional hazards modelSite of originTubal originWorse survivalReplacement therapyOvarian tumorsCancer survivalOvarian cancerPathology reportsOnly subtypeBRCA1/2 mutationsHazards modelObjectivesRecent studiesTumors
2013
Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2
McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2. Journal Of The National Cancer Institute 2013, 105: 141-148. PMID: 23257159, PMCID: PMC3611851, DOI: 10.1093/jnci/djs494.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerOvarian cancerBRCA2 mutationsLong-term survival benefitOvarian cancer-specific survivalCancer-specific survivalOvarian cancer survivalSerous ovarian cancerShort-term survival advantageBRCA1 mutation carriersLong-term survivalHazard ratioSurvival benefitBetter prognosisUnselected womenBRCA2 carriersCancer survivalMutation carriersSurvival advantageSurvival analysisCancerDiagnosisTime pointsWomenSurvival
2012
Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer
Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Yu H. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 2012, 33: 2119-2125. PMID: 22822098, DOI: 10.1093/carcin/bgs243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialCircular DichroismCohort StudiesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialNeoplastic Stem CellsNucleic Acid ConformationOvarian NeoplasmsPolymorphism, Single NucleotidePrognosisPromoter Regions, GeneticQuantitative Trait LociReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerRNA-Binding ProteinsSurvival RateConceptsSingle nucleotide polymorphismsOvarian cancerEpithelial ovarian cancer survivalCancer-related risk factorsEpithelial ovarian cancerOvarian cancer survivalOvarian cancer prognosisHigher mortality riskCell-associated markersPrimary EOC tissuesLin-28BStem cell-associated markersAssociation of genotypesDominant modelPatient survivalSurvival outcomesBorderline significanceEOC tissuesCancer survivalRisk factorsReal-time PCRMortality riskCancer prognosisMultivariate analysisPotential biomarkersHeight, weight, BMI and ovarian cancer survival
Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, Sun P, Narod SA. Height, weight, BMI and ovarian cancer survival. Gynecologic Oncology 2012, 127: 83-87. PMID: 22713293, DOI: 10.1016/j.ygyno.2012.05.038.Peer-Reviewed Original ResearchConceptsBody mass indexOvarian cancer survivalOvarian cancer-specific mortalityCancer-specific mortalityHazard ratioCancer survivalOvarian cancerLarge population-based studyBMI 5 yearsFatal gynecologic malignancyPopulation-based studyEpithelial ovarian cancerConfidence intervalsOvarian cancer prognosisProportional hazards modelChart reviewGynecologic malignanciesClinicopathologic featuresHistologic subtypeMass indexVital statusModifiable factorsRisk factorsHazards modelCancer prognosis
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics